9 results on '"Ruaño, Gualberto"'
Search Results
2. Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder.
- Author
-
Ruaño G, Szarek BL, Villagra D, Gorowski K, Kocherla M, Seip RL, Goethe JW, and Schwartz HI
- Subjects
- Alleles, Cohort Studies, Cytochrome P-450 CYP2D6 genetics, Depressive Disorder, Major genetics, Female, Genotype, Hospitals, Psychiatric, Humans, Inpatients, Length of Stay, Male, Prospective Studies, Cytochrome P-450 CYP2D6 metabolism, Depressive Disorder, Major enzymology, Depressive Disorder, Major therapy
- Abstract
Aim: This study aimed to determine the effect of the CYP2D6 genotype on the length of hospitalization stay for patients treated for major depressive disorder., Methods: A total of 149 inpatients with a diagnosis of major depressive disorder at the Institute of Living, Hartford Hospital (CT, USA), were genotyped to detect altered alleles in the CYP2D6 gene. Prospectively defined drug metabolism indices (metabolic reserve, metabolic alteration and allele alteration) were determined quantitatively and assessed for their relationship to length of hospitalization stay., Results: Hospital stay was significantly longer in deficient CYP2D6 metabolizers (metabolic reserve <2) compared with functional or suprafunctional metabolizers (metabolic reserve ≥2; 7.8 vs 5.7 days, respectively; p = 0.002)., Conclusion: CYP2D6 enzymatic functional status significantly affected length of hospital stay, perhaps due to reduced efficacy or increased side effects of the medications metabolized by the CYP2D6 isoenzyme. Functional scoring of CYP2D6 alleles may have a substantial impact on the quality of care, patient satisfaction and the economics of psychiatric treatment.
- Published
- 2013
- Full Text
- View/download PDF
3. Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9, CYP2C19 and CYP2D6 genes.
- Author
-
Villagra D, Goethe J, Schwartz HI, Szarek B, Kocherla M, Gorowski K, Windemuth A, and Ruaño G
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Alleles, Aryl Hydrocarbon Hydroxylases metabolism, Child, Child, Preschool, Cytochrome P-450 CYP2C19, Cytochrome P-450 CYP2C9, Cytochrome P-450 CYP2D6 metabolism, Female, Genetic Association Studies, Genetic Loci, Genotype, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide, Aryl Hydrocarbon Hydroxylases genetics, Cytochrome P-450 CYP2D6 genetics, Pharmaceutical Preparations metabolism
- Abstract
Aims: We aim to demonstrate clinical relevance and utility of four novel drug-metabolism indices derived from a combinatory (multigene) approach to CYP2C9, CYP2C19 and CYP2D6 allele scoring. Each index considers all three genes as complementary components of a liver enzyme drug metabolism system and uniquely benchmarks innate hepatic drug metabolism reserve or alteration through CYP450 combinatory genotype scores., Methods: A total of 1199 psychiatric referrals were genotyped for polymorphisms in the CYP2C9, CYP2C19 and CYP2D6 gene loci and were scored on each of the four indices. The data were used to create distributions and rankings of innate drug metabolism capacity to which individuals can be compared. Drug-specific indices are a combination of the drug metabolism indices with substrate-specific coefficients., Results: The combinatory drug metabolism indices proved useful in positioning individuals relative to a population with regard to innate drug metabolism capacity prior to pharmacotherapy. Drug-specific indices generate pharmacogenetic guidance of immediate clinical relevance, and can be further modified to incorporate covariates in particular clinical cases., Conclusions: We believe that this combinatory approach represents an improvement over the current gene-by-gene reporting by providing greater scope while still allowing for the resolution of a single-gene index when needed. This method will result in novel clinical and research applications, facilitating the translation from pharmacogenomics to personalized medicine, particularly in psychiatry where many drugs are metabolized or activated by multiple CYP450 isoenzymes.
- Published
- 2011
- Full Text
- View/download PDF
4. Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients.
- Author
-
Ruaño G, Villagra D, Szarek B, Windemuth A, Kocherla M, Gorowski K, Berrezueta C, Schwartz HI, and Goethe J
- Subjects
- Adolescent, Adult, Aged, Aryl Hydrocarbon Hydroxylases genetics, Aryl Hydrocarbon Hydroxylases metabolism, Biomarkers blood, Body Mass Index, Cholesterol, HDL blood, Cholesterol, LDL blood, Cohort Studies, Cytochrome P-450 CYP2C19, Cytochrome P-450 CYP2C9, Cytochrome P-450 CYP2D6 genetics, Cytochrome P-450 CYP2D6 metabolism, Cytochrome P-450 Enzyme System genetics, Depressive Disorder, Major complications, Depressive Disorder, Major drug therapy, Depressive Disorder, Major metabolism, Dyslipidemias complications, Female, Genotype, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide, Psychotropic Drugs therapeutic use, Risk Factors, Triglycerides blood, Cytochrome P-450 Enzyme System metabolism, Dyslipidemias metabolism, Psychotropic Drugs metabolism
- Abstract
Aims: To investigate associations between novel human cytochrome P450 (CYP450) combinatory (multigene) and substrate-specific drug metabolism indices, and elements of metabolic syndrome, such as low density lipoprotein cholesterol (LDLc), high density lipoprotein cholesterol (HDLc), triglycerides and BMI, using physiogenomic analysis., Methods: CYP2C9, CYP2C19 and CYP2D6 genotypes and clinical data were obtained for 150 consecutive, consenting hospital admissions with a diagnosis of major depressive disorder and who were treated with psychotropic medications. Data analysis compared clinical measures of LDLc, HDLc, triglyceride and BMI with novel combinatory and substrate-specific CYP450 drug metabolism indices., Results: We found that a greater metabolic reserve index score is related to lower LDLc and higher HDLc, and that a greater metabolic alteration index score corresponds with higher LDLc and lower HLDc values. We also discovered that the sertraline drug-specific indices correlated with cholesterol and triglyceride values., Conclusions: Overall, we demonstrated how a multigene approach to CYP450 genotype analysis yields more accurate and significant results than single-gene analyses. Ranking the individual with respect to the population represents a potential tool for assessing risk of dyslipidemia in major depressive disorder patients who are being treated with psychotropics. In addition, the drug-specific indices appear useful for modeling a variable of potential relevance to an individual's risk of drug-related dyslipidemia.
- Published
- 2011
- Full Text
- View/download PDF
5. Implementing genotype-guided antithrombotic therapy.
- Author
-
Seip RL, Duconge J, and Ruaño G
- Subjects
- Anticoagulants pharmacology, Aryl Hydrocarbon Hydroxylases genetics, Clopidogrel, Cost-Benefit Analysis, Cytochrome P-450 CYP2C19, Cytochrome P-450 CYP2C9, Cytochrome P-450 Enzyme System genetics, Cytochrome P450 Family 4, Dose-Response Relationship, Drug, Genetic Privacy, Genotype, Health Policy, Humans, Mixed Function Oxygenases genetics, Piperazines pharmacology, Piperazines therapeutic use, Platelet Aggregation Inhibitors pharmacology, Polymorphism, Single Nucleotide, Prasugrel Hydrochloride, Precision Medicine, Purinergic P2 Receptor Antagonists, Thiophenes pharmacology, Thiophenes therapeutic use, Ticlopidine analogs & derivatives, Ticlopidine pharmacology, Ticlopidine therapeutic use, Vitamin K Epoxide Reductases, Warfarin pharmacology, Warfarin therapeutic use, Anticoagulants therapeutic use, Pharmacogenetics, Platelet Aggregation Inhibitors therapeutic use
- Abstract
Genotyping has the potential to improve the efficacy and safety of major antithrombotic drugs. For warfarin, the stable maintenance dose varies from 1-10 mg/day. The VKORC1 -1639G>A allele and the CYP2C9*2 and *3 alleles (cumulative frequency: 90% in Asians, 65% in Europeans and 20% in Africans), explain 45% of response variability in European and 30% in African populations. The large clinical trials COAG and EU-PACT will define the extent to which pharmacogenetic dosing affects the safety and efficacy of warfarin and coumarin derivatives. The platelet inhibitor clopidogrel requires activation by the CYP2C19 enzyme. CYP2C19*2 and *3 alleles (cumulative frequency: 20-50%) produce null enzyme activity, and their presence attenuates platelet inhibition and increases cardiovascular events. The US FDA-mandated drug labeling recognizes the relevance of genotyping in the selection and dosing of both warfarin and clopidogrel.
- Published
- 2010
- Full Text
- View/download PDF
6. Increased carrier prevalence of deficient CYP2C9, CYP2C19 and CYP2D6 alleles in depressed patients referred to a tertiary psychiatric hospital.
- Author
-
Ruaño G, Villagra D, Rahim US, Windemuth A, Kocherla M, Bower B, Szarek BL, and Goethe JW
- Abstract
Objective: This study compared the types and carrier prevalences of clinically significant DNA polymorphisms in the cytochrome P450 (CYP450) genes CYP2C9, CYP2C19 and CYP2D6 in major depressive disorder patients with a control group of nonpsychiatrically ill, medical outpatients., Method: We conducted a case-control study using 73 psychiatric outpatients diagnosed with depression and referred to a tertiary center, The Institute of Living (Hartford, CT, USA), for treatment resistance or intolerable side-effects to psychotropic drugs. The controls were 120 cardiovascular patients from Hartford Hospital being treated for dyslipidemia but otherwise healthy and not psychiatrically ill. DNA typing to detect polymorphisms in the genes CYP2C9, CYP2C19 and CYP2D6 was accomplished with the Tag-It™ mutation detection assay and the Luminex xMAP
® system., Results: The percentage of individuals in psychiatric versus control groups with two wild-type alleles for CYP2C9, CYP2C19 and CYP2D6 genes, were 50 versus 74% (p < 0.001), 71 versus 73% (not statistically significant) and 36 versus 43% (trend, p < 0.2), respectively. Within the psychiatric population, 57% of individuals were carriers of non-wild-type alleles for 2-3 genes, compared with 36% in the control population (p < 0.0001). The balance, 43% in the psychiatric population and 64% in the control, were carriers of non-wild-type alleles for none or one gene., Conclusions: These findings reveal that clinically relevant CYP2C9 polymorphisms occur more frequently in depressed psychiatric patients than in nonpsychiatric controls. The same trend was found for polymorphisms in the CYP2D6 gene. We found a significant cumulative metabolic deficiency in the psychiatric population for combinations of the CYP2C9, CYP2C19 and CYP2D6 genes. The significant enrichment of CYP2C9-deficient alleles in the psychiatric population validates a previously reported association of this gene with the risk for depression disorders. The high prevalence of carriers with deficient and null alleles suggests that CYP450 DNA typing may play a role in the management of psychiatric patients at tertiary care institutions.- Published
- 2008
- Full Text
- View/download PDF
7. High carrier prevalence of combinatorial CYP2C9 and VKORC1 genotypes affecting warfarin dosing.
- Author
-
Ruaño G, Thompson PD, Villagra D, Bower B, Kocherla M, Yazdanpanah G, Seip RL, Windemuth A, White CM, Duconge J, Holford TR, and Wu AH
- Abstract
Background: Polymorphisms in the cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) genes significantly alter the effective warfarin dose. The CYP2C9*2 (430C>T), CYP2C9*3 (1075A>C) and VKORC1 -1639 G>A polymorphisms affect warfarin dose through altered metabolism (CYP2C9) and sensitivity (VKORC1)., Objective: We determined the frequencies of SNPs in the CYP2C9 and VKORC1 genes in a clinical outpatient population and the carrier prevalences for a variety of genotype combinations to gauge the impact of these polymorphisms on warfarin dosage using published algorithms., Method: A total of 127 patients from an outpatient clinic at Hartford Hospital (Hartford, CT, USA) were genotyped for five SNPs in the CYP2C9 gene and seven SNPs in the VKORC1 gene using Luminex
® technology., Results: The polymorphism frequencies were 10.2, 7.9 and 37.4% for the functionally deficient CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms, respectively. Combining prevalence of combinatorial genotypes, 18% were carriers of both CYP2C9 and VKORC1 polymorphisms, 13% were CYP2C9 polymorphism carriers only, 42.5% were VKORC1 carriers only, and the remaining 27% were noncarriers for either gene. Based on published warfarin dosing algorithms, carriers of 1, 2, 3 and 4 functionally deficient polymorphisms predict reductions of 1.0 to 1.6, 2.0 to 2.9, 2.9 to 3.7, and 3.6 to 4.4 mg/day, respectively, in warfarin dose., Conclusion: Overall, 73% of the population carried at least one polymorphism predicting deficient warfarin metabolism or responsiveness and 18% were carriers for polymorphisms in both genes studied. Combinatorial genotyping of CYP2C9 and VKORC1 can allow for individualized dosing of warfarin amongst patients with gene polymorphisms potentially reducing the risk of accentuated responses and bleeding.- Published
- 2008
- Full Text
- View/download PDF
8. High carrier prevalence of deficient and null alleles of CYP2 genes in a major USA hospital: implications for personalized drug safety.
- Author
-
Ruaño G, Makowski G, Windemuth A, Kocherla M, Weiss S, Goethe JW, Bower B, Wu AH, and Thompson PD
- Abstract
Many drugs are metabolized by highly polymorphic cytochrome P450 (CYP) enzymes. Among these enzymes, members of the CYP2 family coded by the CYP2D6, CYP2C9 and CYP2C19 genes are best amenable to the precise prediction of an individual's innate capacity to metabolize drugs by DNA typing of inherited null and deficient alleles. We determined the frequency of these alleles and the prevalence of their carriers in a New England, USA, tertiary care center to assess underlying population genetic features for the practice of personalized medicine. We determined that 54, 25 and 27% are carriers of at least one deficient or null allele for the CYP2D6, CYP2C9 and CYP2C19 genes, respectively. Furthermore, 6% of individuals are carriers of two null alleles for CYP2D6 and are predicted to have no biochemical activity for this isoenzyme. These results support the implementation of DNA typing of CYP2 genes to diagnose adverse drug reactions and to prevent a substantial number of patients being prescribed drugs they cannot adequately metabolize.
- Published
- 2006
- Full Text
- View/download PDF
9. Personalizing public health.
- Author
-
Holford TR, Windemuth A, and Ruaño G
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.